Mirum Pharmaceuticals global controller sells $65,800 in stock By Investing.com

Jolanda Howe, Senior Vice President and Global Controller at Mirum Pharmaceuticals, Inc. (), sold shares of the company’s common stock on September 2, 2026.

Ms. Howe disposed of 658 shares at a price of $100 per share, totaling $65,800. Following this transaction, Ms. Howe directly holds 616 shares of Mirum Pharmaceuticals common stock. The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Ms. Howe on March 18, 2026.The insider sale comes as MIRM stock trades near $100.63, with shares up 27% year-to-date. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value estimate. Investors can access detailed valuation metrics and exclusive Pro Research Reports covering MIRM and 1,400+ other US equities on the platform.

In other recent news, Mirum Pharmaceuticals reported second-quarter net product sales of $176 million, surpassing the forecast of $166.03 million. The company also raised its full-year 2026 sales outlook. Despite this positive performance, investors seemed concerned about the later-than-expected filing timeline for volixibat in primary sclerosing cholangitis, leading to a significant drop in the stock price after hours. In terms of analyst ratings, Citizens reiterated a Market Outperform rating with a price target of $137.00 for Mirum Pharmaceuticals. They highlighted the promising interim AZURE-1 data, which they believe confirms the potential of brelovitug in the HDV landscape. Similarly, H.C. Wainwright reiterated a Buy rating with a price target of $140.00, maintaining a positive outlook on the company’s prospects. These developments reflect the ongoing interest and analysis from the investment community regarding Mirum Pharmaceuticals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.